Back to top
more

Immix Biopharma (IMMX)

(Delayed Data from NSDQ)

$2.05 USD

2.05
119,258

+0.01 (0.49%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $2.03 -0.02 (-0.98%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IMMX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Immix Biopharma, Inc. [IMMX]

Reports for Purchase

Showing records 1 - 20 ( 51 total )

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

07/10/2024

Company Report

Pages: 2

US CAR-T trial commences patient dosing

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 10.00

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

06/27/2024

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

05/20/2024

Company Report

Pages: 5

All roads lead to NEXICART-2

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 10.00

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

04/03/2024

Company Report

Pages: 11

Reaffirmed long-term focus on outpatient CAR-T

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 25.00

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

03/26/2024

Company Report

Pages: 2

Marching towards US clinical trials for NXC-201

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 10.00

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

02/27/2024

Company Report

Pages: 2

2023 recap with a preview of active year ahead

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 10.00

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

02/12/2024

Company Report

Pages: 2

Updates galore: NXC-201 ODD (EU) and raise

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 10.00

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

02/07/2024

Company Report

Pages: 2

Increased legroom following common-only raise

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 10.00

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

12/12/2023

Company Report

Pages: 2

Encouraging stream of ALA data newsflow

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

12/11/2023

Company Report

Pages: 5

100% ORR Continues for NXC-201 in ALA, 10 Patients Evaluated Thus Far

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

12/11/2023

Daily Note

Pages: 5

Mid-Day Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

12/01/2023

Company Report

Pages: 2

Glimmer of hope for ALA patients

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

11/30/2023

Daily Note

Pages: 10

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

11/30/2023

Company Report

Pages: 6

KOL Call Underscores Unmet ALA Need NXC-201''s Potential & Opportunity

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

11/22/2023

Daily Note

Pages: 2

CAR-T trial moves to US with outpatient potential

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

11/17/2023

Company Report

Pages: 6

A quarter of progress for both lead assets

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 12.50

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

10/10/2023

Company Report

Pages: 10

A step toward delivering a practical CAR-T option

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 12.50

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

10/03/2023

Company Report

Pages: 5

New NXC-201 ALA Data - 100% ORR 67% CR In Heavily Refractory Patients

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

10/02/2023

Company Report

Pages: 6

Updated NXC-201 Results Show Continued Potency in Rel/Ref MM Patients

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Immix Biopharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

09/22/2023

Company Report

Pages: 2

NXC-201 gains orphan drug designation in ALA

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party